Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Non-injectable Insulin Market From 2025 to 2029?

In recent times, the market size for non-injectable insulin has seen a swift expansion. The market is expected to surge from $1.92 billion in 2024 to $2.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.1%. Key factors contributing to this growth during the historic period include improvements in patient adherence, mitigation of needle fear, enhancements in quality of life, simplicity in application, and effective control of blood sugar levels.

In the coming years, the market for non-injectable insulin is projected to witness robust expansion. It is expected to rise to “$3.11 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 9.8%. The forecasted growth is due to several factors, including the emphasis on maintaining patient compliance, resolving persistent fear of needles, enhancing quality of life, increasing safety measures, and minimizing the risk of infections and injuries. Key trends expected during this period are advancements in technology, evolutionary technological solutions, incorporation of digital health, application of nanotechnology, and combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Elements Are Contributing To Growth In The Non-injectable Insulin Market?

The escalating problems of obesity and diabetes are anticipated to fuel the expansion of the non-injectable insulin market. Obesity, marked by an abnormal pile-up of body fat due to an imbalance in energy consumption and expenditure, and diabetes mellitus, commonly known as diabetes and distinguished by prolonged periods of high blood sugar levels, are two conditions that increasingly warrant the use of non-injectable insulin. This form of insulin is utilized in the treatment of diabetes and obesity and has the capacity to augment disease management by overcoming obstacles to insulin therapy, providing potential weight management benefits, and supplying more user-friendly treatment alternatives. For example, the World Heart Federation, a non-governmental organization based in Switzerland, projected in 2022 a steep rise in global obesity rates. An estimation reveals that 2.3 billion people, including children and adults, struggled with overweight and obesity issues in 2021, but this figure is expected to escalate to 2.7 billion by 2025. Moreover, a report released by the British Diabetic Association, a diabetes charity based in the UK, revealed in April 2023 that 4.3 million people in the UK have diabetes and over 2.4 million UK residents are at a high risk of developing type 2 diabetes. The 2021-22 registration data shows an increase of 148,951 compared to the past year. This surge in obesity and diabetes thus stands as the driving factor for the expansion of the non-injectable insulin market.

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Which Emerging Trends And Strategic Shifts Are Shaping The Non-injectable Insulin Market?

Leading businesses in the non-injectable insulin market are prioritizing innovative improvements in drug delivery systems, with a focus on painless, needle-free alternatives such as oral insulin sprays, to better the lives of those dependent on multiple insulin injections for their diabetes management. These sprays serve as a convenient method of regulating blood sugar as they can easily be sprayed directly into the patient’s mouth. NiedlFree Technologies, an Indian tech platform, launched Ozulin, an oral insulin spray, in November 2023 as an example of this invention. This spray aims to provide a user-friendly substitute for people with diabetes, especially those who find the traditional insulin injection methods daunting. Ozulin, if approved, has the potential to revolutionalize the treatment of diabetes by offering a more convenient, and painless alternative to insulin injections.

Who Are The Key Contributors To Growth In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Is Projected To Lead The Non-injectable Insulin Market By 2025?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model